261 related articles for article (PubMed ID: 25368228)
21. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives.
Mirghani H; Amen F; Tao Y; Deutsch E; Levy A
Cancer Treat Rev; 2015 Dec; 41(10):844-52. PubMed ID: 26476574
[TBL] [Abstract][Full Text] [Related]
22. In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status.
Reid P; Wilson P; Li Y; Marcu LG; Staudacher AH; Brown MP; Bezak E
PLoS One; 2017; 12(10):e0186186. PubMed ID: 29028842
[TBL] [Abstract][Full Text] [Related]
23. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs as new biomarkers for human papilloma virus related head and neck cancers.
Wang Y; Wang J; Huang Y
Cancer Biomark; 2015; 15(3):213-8. PubMed ID: 25769448
[TBL] [Abstract][Full Text] [Related]
26. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
Rieckmann T; Tribius S; Grob TJ; Meyer F; Busch CJ; Petersen C; Dikomey E; Kriegs M
Radiother Oncol; 2013 May; 107(2):242-6. PubMed ID: 23602369
[TBL] [Abstract][Full Text] [Related]
27. HPV, hypoxia and radiation response in head and neck cancer.
Göttgens EL; Ostheimer C; Span PN; Bussink J; Hammond EM
Br J Radiol; 2019 Jan; 92(1093):20180047. PubMed ID: 29493265
[TBL] [Abstract][Full Text] [Related]
28. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
29. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.
Lassen P
Radiother Oncol; 2010 Jun; 95(3):371-80. PubMed ID: 20493569
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence.
Schlecht NF
Oncol Rep; 2005 Nov; 14(5):1239-47. PubMed ID: 16211291
[TBL] [Abstract][Full Text] [Related]
31. The role of human papillomavirus in head and neck cancer.
Lajer CB; von Buchwald C
APMIS; 2010 Jun; 118(6-7):510-9. PubMed ID: 20553531
[TBL] [Abstract][Full Text] [Related]
32. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.
Wijffels KI; Marres HA; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH
Oral Oncol; 2008 Apr; 44(4):335-44. PubMed ID: 17689286
[TBL] [Abstract][Full Text] [Related]
33. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.
Busch CJ; Kriegs M; Laban S; Tribius S; Knecht R; Petersen C; Dikomey E; Rieckmann T
Radiother Oncol; 2013 Sep; 108(3):495-9. PubMed ID: 23932155
[TBL] [Abstract][Full Text] [Related]
34. M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF.
Fu E; Liu T; Yu S; Chen X; Song L; Lou H; Ma F; Zhang S; Hussain S; Guo J; Sun J; Yu P; Mao X; Wei L
Oncol Rep; 2020 Aug; 44(2):698-710. PubMed ID: 32627036
[TBL] [Abstract][Full Text] [Related]
35. Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index.
Azzimonti B; Pagano M; Mondini M; De Andrea M; Valente G; Monga G; Tommasino M; Aluffi P; Landolfo S; Gariglio M
Histopathology; 2004 Dec; 45(6):560-72. PubMed ID: 15569046
[TBL] [Abstract][Full Text] [Related]
36. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance.
Braakhuis BJ; Brakenhoff RH; Meijer CJ; Snijders PJ; Leemans CR
Eur J Cancer; 2009 Nov; 45(17):2935-9. PubMed ID: 19766476
[TBL] [Abstract][Full Text] [Related]
37. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer.
Nygård M; Aagnes B; Bray F; Møller B; Mork J
Eur J Cancer; 2012 Jun; 48(9):1341-6. PubMed ID: 22516210
[TBL] [Abstract][Full Text] [Related]
38. Detection of human papillomavirus (HPV) type 6, 16 and 18 in head and neck squamous cell carcinomas by in situ hybridization.
Cerovac Z; Sarcević B; Kralj Z; Ban J
Neoplasma; 1996; 43(3):185-94. PubMed ID: 8841506
[TBL] [Abstract][Full Text] [Related]
39. Performance of the Roche cobas 4800 high-risk human papillomavirus test in cytologic preparations of squamous cell carcinoma of the head and neck.
Kerr DA; Pitman MB; Sweeney B; Arpin RN; Wilbur DC; Faquin WC
Cancer Cytopathol; 2014 Mar; 122(3):167-74. PubMed ID: 24259368
[TBL] [Abstract][Full Text] [Related]
40. The role of Glial cell derived neurotrophic factor in head and neck cancer.
Cao H; He Q; Eyben RV; Bloomstein J; Nambiar DK; Viswanathan V; Aggarwal S; Kwok S; Liang R; Koong AJ; Lewis JS; Kong C; Xiao N; Le QT
PLoS One; 2020; 15(2):e0229311. PubMed ID: 32084217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
